Evidence map›Paper›PMID 32286246›Full record

ArticleClinical chemistry and laboratory medicine2020

COVID-19 infections are also affected by human ACE1 D/I polymorphism.

Joris R Delanghe, Marijn M Speeckaert, Marc L De Buyzere

Open access · bronzeAbstract readLetter
PubMed Publisher
In one paragraph

Article in Clinical chemistry and laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The I/D variant of theFuture science OA · 2025
    Article
  4. Article
  5. Article
  6. Are COVID-19 Polymorphisms in ACE and ACE2 Prognosis Predictors?Current issues in molecular biology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.European journal of drug metabolism and pharmacokinetics · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Joris R DelangheDepartment of Clinical Chemistry, Ghent University, C. Heymanslaan 10, 9000 Gent, Belgium.ORCID https://orcid.org/0000-0002-5702-6792
Marijn M SpeeckaertDepartment of Internal Medicine, Ghent University, Ghent, Belgium.
Marc L De BuyzereDepartment of Internal Medicine, Ghent University, Ghent, Belgium.
Ghent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BetacoronavirusComplement C3Coronavirus InfectionsCOVID-19HaptoglobinsHemochromatosis ProteinHumansINDEL MutationPandemicsPeptidyl-Dipeptidase APneumonia, ViralPolymorphism, GeneticPrevalenceSARS-CoV-2Vitamin D-Binding ProteinACE protein, humanComplement C3HaptoglobinsHemochromatosis ProteinHFE protein, humanPeptidyl-Dipeptidase AVitamin D-Binding Proteinangiotensin-converting enzymeCOVID-19plasma proteinspolymorphism

Identifiers

PMID32286246
OpenAlexW3015575322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.